New drug ABBV-324 enters first human tests for tough cancers
NCT ID NCT06858813
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 25 times
Summary
This early-stage study tests an experimental drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular cancer) or a type of lung cancer (squamous non-small cell lung cancer). The main goals are to check safety and see if the drug shrinks tumors. Participants receive ABBV-324 alone or a standard drug (lenvatinib) for comparison. The study lasts about 6.5 years and involves regular hospital visits, blood tests, and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120
RECRUITINGIrvine, California, 92618, United States
-
City of Hope National Medical Center /ID# 270526
RECRUITINGDuarte, California, 91010, United States
-
Fdi Clinical Research /ID# 272960
COMPLETEDSan Juan, 00927, Puerto Rico
-
Hadassah Medical Center-Hebrew University /ID# 271235
RECRUITINGJerusalem, 91120, Israel
-
Hospital Universitario Fundacion Jimenez Diaz /ID# 272718
RECRUITINGMadrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro /ID# 272719
RECRUITINGMadrid, 28050, Spain
-
Kansai Medical University Hospital /ID# 272884
RECRUITINGHirakata-shi, Osaka, 573-1191, Japan
-
Memorial Sloan Kettering Cancer Center /ID# 271228
RECRUITINGNew York, New York, 10021-3459, United States
-
Nanfang Hospital - Southern Medical University /ID# 276916
RECRUITINGGuangzhou, Guangdong, 510000, China
-
National Cancer Center Hospital /ID# 270583
RECRUITINGChuo-Ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East /ID# 270585
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
National Taiwan University Hospital /ID# 270593
RECRUITINGTaipei, 100, Taiwan
-
Rabin Medical Center. /ID# 271236
RECRUITINGPetah Tikva, 4941492, Israel
-
Rambam Health Care Campus /ID# 270604
RECRUITINGHaifa, 3109601, Israel
-
SCRI Oncology Partners /ID# 272750
RECRUITINGNashville, Tennessee, 37203, United States
-
Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
UC Irvine Medical Center /ID# 270507
RECRUITINGOrange, California, 92868-3201, United States
-
UCLA - Santa Monica /ID# 275995
RECRUITINGSanta Monica, California, 90404, United States
-
USC Norris Comprehensive Cancer Center /ID# 271573
RECRUITINGLos Angeles, California, 90033, United States
-
University of Chicago Medical Center /ID# 270517
RECRUITINGChicago, Illinois, 60637, United States
-
Washington University /ID# 275757
RECRUITINGSt Louis, Missouri, 63110, United States
-
Zhongshan Hospital Fudan University /ID# 276917
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.